中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

330 records (took 0.034 seconds)

    VACCINES AGAINST TICK-BORNE DISEASES
    101.
    发明申请
    VACCINES AGAINST TICK-BORNE DISEASES 审中-公开

    公开(公告)号：US20200164055A1

    公开(公告)日：2020-05-28

    申请号：US16631964

    申请日：2018-07-17

    Applicant: Kansas State University Research Foundation

    Inventor： Roman R. Ganta

    IPC: A61K39/02 ,  A61P31/04 ,  A61K39/00

    Abstract: The present disclosure provides immunogenic compositions and vaccines effective for reducing the incidence of or severity of clinical signs or symptoms of infection by a tick-borne pathogen selected from the group consisting of Rickettsia rickettsii, Ehrlichia chaffeensis, Ehrlichia canis, Ehrlichia ruminantium, Anaplasma marginale, and Anaplasma phagocytophilum. In preferred forms, the immunogenic composition comprises an inactivated whole cell bacteria selected from the group consisting of Rickettsia rickettsii, Ehrlichia chaffeensis, Ehrlichia canis, Ehrlichia ruminantium, Anaplasma marginale, Anaplasma phagocytophilum, and any combination thereof, together with an adjuvant.

    High-throughput fluorescent screening assay for inhibitors of gram-negative bacterial iron uptake
    103.
    发明授权
    High-throughput fluorescent screening assay for inhibitors of gram-negative bacterial iron uptake 有权

    公开(公告)号：US10604782B2

    公开(公告)日：2020-03-31

    申请号：US15739065

    申请日：2016-07-01

    Applicant: Kansas State University Research Foundation

    Inventor： Phillip E. Klebba ,  Salete M. Newton ,  Brittany L. Nairn ,  Mathew Hanson

    IPC: C12Q1/02 ,  C07K14/21 ,  C12N1/20

    Abstract: A cell-based assay for identifying a compound that inhibits iron transport in Gram-negative bacteria, engineered bacterial cells, and kits for conducting the same. The assay involves contacting a candidate compound with an engineered Gram-negative bacteria in the presence of iron for a sufficient period of time, exposing the reaction solution to an energy source to generate the detectable signal, and detecting changes in the detectable signal in the reaction solution over time. The engineered Gram-negative bacteria comprises an iron transport protein on its outer membrane that comprises an amino acid residue that has been engineered with a detectable label that generates a detectable signal. The changes in the detectable signal in the assay system over time correspond to the effect of the candidate compound on iron transport in the Gram-negative bacteria.

    MICROBIOME TRANSPLANTATION
    104.
    发明申请
    MICROBIOME TRANSPLANTATION 审中-公开

    公开(公告)号：US20200078419A1

    公开(公告)日：2020-03-12

    申请号：US16692411

    申请日：2019-11-22

    Applicant: Kansas State University Research Foundation

    Inventor： Megan C. Niederwerder

    IPC: A61K35/745 ,  A23K50/30 ,  A23K10/18

    Abstract: The present disclosure provides compositions and methods for improving disease resistance, increasing weight gain, and reducing the incidence and/or severity of clinical signs of infection. The composition generally comprises one or more microorganisms that is administered to an animal in need thereof. Preferred infections that can be combated with the compositions and methods of this disclosure are respiratory infections including PRRSV and PCV2.

    Co-detection and association of multiple genes from the same genome in a sample
    106.
    发明授权
    Co-detection and association of multiple genes from the same genome in a sample 有权

    公开(公告)号：US10233505B2

    公开(公告)日：2019-03-19

    申请号：US15543712

    申请日：2016-01-15

    Applicant: Kansas State University Research Foundation

    Inventor： Jianfa Bai ,  Xuming Liu ,  Gary Anderson

    IPC: C12Q1/689

    Abstract: The present invention is concerned with PCR-based detection methods and kits for the identification, differentiation, and quantification of different bacterial strains (e.g., Gram-negative bacterial strains), and also association of two or more PCR-positive genes to a single genome. The methods generally comprise carrying out PCR reactions using at least a first PCR primer set and/or probe for at least one target nucleic acid; and a second PCR primer set and/or probe for at least a second target nucleic acid. Positive PCR reaction products are then detected to determine test samples containing positive PCR reaction products for both the first and second target nucleic acids. This information can be used to calculate the gene association rate to determine whether the sample contains, for example, Shiga toxin-producing E. coli of the O-type serogroup.

Patent Agency Ranking